Archive: 2 14 2013
Targeting the B-cell Receptor in Aggressive B-cell Lymphomas
Stockholm, June 14, 2013 Dr Wyndham Wilson will give an update on recent developments in the treatment of lymphomas with small molecules. The last 30 years have seen a plethora of treatments for diffuse large B-cell lymphoma (DLBCL) but few advances have been made. Recent studies have identified B-cell receptor signaling as critical for many B-cell lymphomas including the most common type, called diffuse large B-cell lymphoma (DLBCL). Recent studies have shown that DLBCL is actually not a single disease but at least 3 different diseases, each with its own critical abnormalities that allow it to survive as a malignancy. The most difficult to treat type of DLBCL is called the Activated B-cell (ABC) subtype, which is dependent on abnormal signaling of the B-cell receptor (BCR). Work by Dr. Lou Staudt has shown that these tumors will die when this pathway is inhibited.
Pomalidomide prolongs survival in refractory myeloma patients
Stockholm, June 14, 2013 Dr Jesus San-Miguel will present promising results of a phase 3 study in multiple myeloma.
Treatment for patients with multiple myeloma (MM) has improved over the last decade due to the introduction of new drugs such as lenalidomide and bortezomib. However, after receiving multiple treatments, MM patients often become resistant (refractory) to these drugs and have an average survival of only 9 months.
Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an…
Stockholm, June 14, 2013 Dr Henk Lokhorst will present the results from a phase I/II study in advanced Multiple Myeloma.
Multiple myeloma is the second most common hematological cancer. It is a cancer of plasma cells and it accounts for approx. 1% of all cancers. At present, no cure is available. The 5-year relative survival rate for multiple myeloma is around 40% so there is a strong need for new treatment modalities to improve the survival.
Mini-hormone fights iron
Stockholm, June 14, 2013 Dr Elizabeta Nemeth will present findings of a study in patients with iron overload disorders that will contribute to the design of a potential new treatment at the 18th Congress of the European Hematology Association in Stockholm.
TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROL…
Stockholm, June 14, 2013 Dr Ross Levine will present the results from a study on targeting the JAK-STAT pathway in myeloproliferative neoplasms.
Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes …
Stockholm, June 14, 2013 Dr Valentin Goede will present promising outcomes for elderly CLL patients at the 18th Congress of the European Hematology Association in Stockholm.